



NASDAQ: NMRD

Better Diagnostics for Life

Corporate Presentation

May 2019

Forward-Looking Statement

This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “estimate,” “future,” “strive,” and similar words. These statements involve many risks and uncertainties that may cause actual results to differ from what may be expressed or implied in these statements. These risks are discussed in Nemaura’s filings with the Securities and Exchange Commission (the “Commission”), including the risks identified under the section captioned “Risk Factors” in Nemaura’s Quarterly Report on Form 10-Q filed with the Commission on February 11, 2019 and in Nemaura’s Form 10-K filed with the Commission on June 12, 2018. Nemaura disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Investment Highlights

- ✓ World's first non-invasive continuous glucose monitor (CGM), targeting \$179B+ opportunity:
 - \$69B+ type II diabetic market & \$50B+ pre-diabetic market & \$60B+ wearable health-tech market
- ✓ Anticipate near-term FDA submission & CE approval
- ✓ Lowest price, high recurring margin model, with lowest COGS per CGM patch in the industry
- ✓ Growing IP portfolio with over 30 issued & pending patents
- ✓ Platform BEAT™ diagnostic technology with robust product pipeline:
 - Launching continuous lactate monitoring (CLM) near term, targeting \$60B+ wearable tech market
 - Pipeline of four other products including non-invasive continuous alcohol monitoring (CAM)
- ✓ Proven management team with successful track records
- ✓ Clean capital structure with no long-term debt

CGM Enables New Standard of Care for Diabetes

CGM currently mostly targets insulin users / type I diabetics. Unmet need for non-insulin users / type II / pre-diabetics

CGM enables AGP = TIR (time in range), a new standard of care:

- **Insulin users:**
Improve daily insulin dosage decisions and reduce daily finger stick frequency
- **Non insulin users:**
Better manage glucose by adopting daily '*time in range*' (TIR) alongside A1c

CGM provides insulin users with alternative to finger stick:

Insulin users (20% of diabetics) have traditionally used multiple (typically 6-8) daily finger stick glucose readings to guide daily insulin dosage decisions

CGM transforms insulin dosage decisions by providing real-time, constant glucose readings, typically at 5 min intervals (12 per hour) which accumulate to provide an **Ambulatory Glucose Profile (AGP) Chart**



CGM provides non-insulin users with alternative to A1c:

Non-insulin users (80% of diabetics) have traditionally mostly used periodic A1c readings (every 3-6 months) to manage glucose levels. A1c is derived from a lab blood test providing a single value representing the average glucose level over past 60-90 days

CGM transforms glucose control for non-insulin users by widening focus from limited 'gold standard' A1c metric to more meaningful 'time in range' (TIR) metric

Limitations of A1c: 'Time in Range' (TIR) Matters More

- CGM collates 288 data points daily (12 x 24 hours) to enable a detailed Ambulatory Glucose Profile (AGP) chart
- **AGP chart enables TIR**
- Diabetics aim to keep A1c below 7% (8.6 mmol/L)
- Three people can have identical 7% A1c with wildly differing 'TIR' (see green band in AGP chart)
- AGP enables real time behavior changes to minimize glucose fluctuations thereby increasing TIR
- Diabetes can be put into remission if glucose levels are constantly maintained in range
- The FDA Device Division (CDRH) recognizes validity of TIR
- Pre-diabetics can also delay or avoid onset of diabetes by improving TIR



Continuous Glucose Monitoring (CGM): TAM

- SugarBEAT® \$179B+ opportunity consists of three target markets:
 - \$69B+ TAM Type II diabetics (95% of all diabetics)¹
 - \$50B+ TAM Pre-diabetics – approximately 3x population²
 - \$60B+ TAM Wearable Health-Tech market – low carb / weight loss / fitness³


U.S. CGM Market Overview ¹

- U.S. has the largest number of CGM users globally (630k in 2018)
- Only 2.6% of 25M US diagnosed diabetics used CGM in 2018
- U.S. annual CGM usage increased by 117% in 2018
- 30% of U.S. type I diabetics use CGM
- 3% of U.S. type II insulin users use CGM
- CGM usage amongst non-insulin diabetics negligible
- U.S. has 84M pre-diabetics

¹ PiperJaffray Company Note DXCM Sep 5 2018

² Assuming 50% usage as compared to type II non insulin market

³ Juniper Research Digital Health Report Jan 14 2019



SugarBEAT® CGM




- World's first non-invasive CGM – sits on top of the skin and does not puncture the skin
- Daily disposable adhesive skin-patch connected to a rechargeable transmitter
- Smartphone App displays glucose readings every five minutes for periods up to 24 hours
- Enables users to spend more time in range by providing an Ambulatory Glucose Profile chart
- Insulin users can adjunctively use SugarBEAT® when calibrated with a finger-stick glucose reading
- CE Mark achieved on predecessor device (wrist-watch format) in Q1 2016




How SugarBEAT® Works

- SugarBEAT® passes a mild, non-perceptible electric current across the skin
- Painlessly draws a small amount of glucose molecules out of the interstitial fluid just below the top layer of skin into a chamber within the patch
- The rechargeable transmitter measures glucose levels within the chamber, and transmits this data every five minutes via Bluetooth
- Using a proprietary algorithm, the app then displays this data as glucose value on smart phone / device
- Watch SugarBEAT® video at:

<https://sugarbeat.com/introducing-sugarbeat/>

 Glucose molecule
 Negative ion
 Positive ion



SugarBEAT[®] Competitive Advantages

Current CGM Patch Inserter



SugarBEAT[®]



Non-Invasive - Painless given patch does not penetrate the skin


Flexible-use - Freedom to decide WHEN, HOW LONG (<24h) & WHERE to wear

Affordable – Significantly lower monthly costs

Environmentally friendly – Rechargeable transmitter Patch inserter NOT required (see image)

Hypo-allergenic - Daily new patch location No skin penetration Gentler silicone based adhesive

Safe -MARD 11.92% with one calibration per day Insulin-dosing decisions with adjunctive finger stick Predictive alerts and real-time CGM capabilities 30 minute warm-up period



Lowest Price High Recurring Margin Lowest COGS Model

- Amongst CGMs, SugarBEAT® achieves lowest price, high recurring gross margins & lowest COGS
- SugarBEAT® can be worn on non-continuous day basis greatly amplifying price saving
- Anticipated gross margins ~70%** driven by lowest COGS per CGM patch in industry

- Non-Insulin users = \$30 / month*
 - 8 Patches / month
 - Annual Subscription
 - Inclusive of transmitter and recharger
- Insulin users = \$55 / month*
 - 16 Patches / month
 - Annual Subscription
 - Inclusive of transmitter and recharger

- SugarBEAT® lowest monthly cost CGM:
- SugarBEAT® \$30 monthly cost* (8 patches)
- Abbot Libre \$100 monthly cost
- Dexcom G6 \$180 monthly cost
- Senseonics \$240 monthly cost

* Indicative pricing - to be confirmed

**Excluding gross margin sharing agreement with distributor in Europe

SugarBEAT® Clinical Data

- Recently completed clinical studies to support FDA submission
 - The clinical studies used were split between Type I and Type II diabetics
 - Consisted of 75 patients over 225 patient days
 - Generated over 12,000 paired data points, with blood samples taken via catheter every 15 minutes over a 12-hour period for three non-consecutive days for each patient
- Study design was based on two previous pre-sub meetings Nemaura held with the FDA, ensuring that the study meet adequacy requirements to provide statistically valid results
- The clinical study results indicated a MARD (Mean Absolute Relative Difference) of 11.92% (with a lower figure denoting greater accuracy), using a single point finger stick calibration
 - No device-related adverse events were noted

SugarBEAT® Regulatory Pathway

- U.S. FDA De-Novo 510(k)
 - ✓ Successfully completed the clinical studies needed to support FDA submission for approval of SugarBEAT® in the USA
 - ✓ Currently preparing the dossier for FDA submission
- European CE Mark
 - ✓ Working closely with British Standards Institute (BSI), the Company's designated European Notified Body, a global leader in accreditation services, on a Fast Track application
 - ✓ On track for CE Mark approval followed by commercial launch later this year

De-Novo 510(k)

- Lower risk (Class II graded medium risk)
- Quicker review process compared with PMA which is Class III graded (higher risk)
- The recent De-Novo and subsequent 510(k) by Dexcom provide evidence that current FDA thinking on invasive CGM devices for therapeutic use are suitable for classification as Class II
- SugarBEAT® is non-invasive and adjunctive, and therefore lower risk




Intellectual Property

- Building an extensive intellectual property portfolio, to position the Company to become a leader in the non-invasive CGM space
- The Company has over thirty patents (~70% approved and ~30% pending) spanning the following six patent families:
 1. Sensor related
 2. Algorithm and methods of using the CGM data
 3. Algorithm related - allowing sensing cycles to be reduced
 4. Devices & methods to enhance glucose sensing
 5. Methods to enhance glucose sensing
 6. Devices and methods to extract glucose
- The Company anticipates filing of a further 60 patents over the course of the next 18 months



SugarBEAT[®] Key Milestones



Current Product Pipeline

| Product | Key Features | Market |
|--|--|--|
| SugarBEAT Gen II | <ul style="list-style-type: none"> • Include pediatric cover • Improved accuracy (MARD) • Longer patch wear time (72 hours) | <ul style="list-style-type: none"> • Type II Diabetics • Pre-Diabetics • Wearable Health-Tech |
| Continuous Lactate Monitoring (anticipated launch Q4 2019) | <ul style="list-style-type: none"> • Worlds only non-invasive skin patch for continuous lactate monitoring • Determines appropriate training intensity levels and monitors progression | <ul style="list-style-type: none"> • Athletes • Fitness • Wearable Health-Tech market expected to be worth \$60B+ by 2023¹ |

¹ Juniper Research Digital Health Report Jan 14 2019

Planned Product Pipeline

| Product | Uses | Diagnostics |
|--------------------|--|--|
| Alcohol Monitoring | Support personal health goals, and provide warnings prior to driving, and provide physicians with individual drinking habits | Prevention of progression to alcohol related diseases. |
| Prostaglandin | Screening for inflammatory irritants in formulations during drug and cosmetic development | Inflammation |
| Lactate | Lactate monitoring in intensive care | Anaerobic Metabolism |
| Various | Monitoring the impact of drug treatment for treatment-regimen calibration and pharmacokinetics | Treatment Regimen Optimization |
| Phenylalanine | Phenylalanine monitoring to ensure that the level is sufficiently suppressed | Phenylketonuria (PKU) |

Senior Management

Dr. Faz Chowdhury, CEO

Dr. Chowdhury is in charge of research and development of the core technologies, product development, innovation and commercialization. Prior to establishing the Company, Dr. Chowdhury was the founder and CEO of Microneedle Technologies and Nemaura Pharma Limited where he played a pivotal role in the development, manufacture and launch of a microneedle device used in skin clinics, which is also currently being evaluated for skin cancer drug delivery. Dr. Chowdhury has been responsible for negotiating licensing deals for a transdermal patch to treat Alzheimer's disease. Additionally, he was involved in negotiations for out-licensing patches to treat Parkinson's and Hypertension, and in-licensing complementary technologies. Dr. Chowdhury originally trained as a pharmaceutical scientist and has an MSc in Microsystems and Nanotechnology from Cranfield University, and a Doctorate from the University of Oxford on nano-drug delivery.

Bashir Timol, Chief Business Officer

Mr. Timol co-founded, managed and funded several biotech and life science companies, and led the investment consortium that provided capital for the initial two funding rounds for Nemaura Medical. Mr. Timol obtained his Bachelor of Arts degree in Economics from the University of Central Lancashire, UK.

Dr. Fred Schaebsdau, Strategy and Business Development Advisor

Dr. Schaebsdau has over 15 years of executive level experience in the CGM, Blood Glucose Monitoring (BGM) and insulin delivery industries, which started in 2004 during his tenure with Abbott Diabetes Care, where he was a member of the M&A and post-merger integration teams responsible for the acquisition of TheraSense and its FreeStyle Navigator CGM. From 2016 until 2019, he was the General Manager of Dexcom Germany, which during his leadership became the fastest growing organization in Dexcom's history achieving triple digit revenue and new patient growth every year. Two generations of CGM, G5 and G6, were successfully launched and negotiations with public insurers completed, which resulted in full reimbursement for >85% of the German population. From 2009 until 2015, at Roche Diabetes Care, he was Sr. VP & Head of Global Strategy and Business Development, completing several strategic acquisitions, partnerships and licensing deals. In 2015, he founded his own firm as exclusive distributor in Europe, Middle East and Africa for UniStrip®, the world's first generic blood glucose test strip. Since 2015, he has been member of the Advisory Board of Peppermint Venture Partners.

Investment Highlights

- ✓ World's first non-invasive continuous glucose monitor (CGM), targeting \$179B+ opportunity:
 - \$69B+ type II diabetic market & \$50B+ pre-diabetic market & \$60B+ wearable health-tech market
- ✓ Anticipate near-term FDA submission & CE approval
- ✓ Lowest price, high recurring margin model, with lowest COGS per CGM patch in the industry
- ✓ Growing IP portfolio with over 30 issued & pending patents
- ✓ Platform BEAT™ diagnostic technology with robust product pipeline:
 - Launching continuous lactate monitoring (CLM) near term, targeting \$60B+ wearable tech market
 - Pipeline of four other products including non-invasive continuous alcohol monitoring (CAM)
- ✓ Proven management team with successful track records
- ✓ Clean capital structure with no long-term debt

Key Statistics

| | |
|--|-----------|
| Ticker: | NMRD |
| Exchange: | NASDAQ |
| Share price (as of 4/26/2019): | \$1.02 |
| Common shares outstanding: | 207.5 M |
| Market Capitalization: | \$211.7 M |
| Options and Warrants (10M @ \$0.50 and 1.9M @ \$1.04): | 11.9M |
| Total Potential Shares Outstanding: | 221.7 M |
| Fiscal year-end: | March 31 |
| Insider ownership (fully diluted): | 58% |